Jerusalem, 3 May, 2026 (TPS-IL) — MSICS Pharma, an Israeli biotechnology company developing medical-grade psilocybin treatments, announced it raised $3.6 million in a funding round led by investors including Fusion VC and GlenRock. The company said it is the only firm in Israel and Europe licensed by the Health Ministry to manufacture psilocybin under Good Manufacturing Practice standards for medical use.
MSICS is conducting Phase II clinical trials targeting treatment-resistant depression and obsessive-compulsive disorder, and plans to launch a multi-center PTSD study with four Israeli hospitals. The company said the new funding will support expanded production capacity, clinical trials, and preparations for entry into international markets.